摘要
目的:探讨非小细胞肺癌(NSCLC)组织中ERCC1表达水平与顺铂(DDP)化疗耐药的相关性。方法:应用免疫组化SP法检测82例NSCLC组织中ERCC1的表达并分析其与DDP化疗耐药的关系。结果:ERCC1表达水平与NSCLC患者年龄、性别、临床分期及组织学类型无关,P>0.05。ERCC1阴性表达组的化疗有效率为53.5%(23/43),而ERCC1阳性表达组的化疗有效率为17.9%(7/39),两组比较差异有统计学意义,χ2=4.76,P=0.04。结论:ERCC1在NSCLC组织中的表达水平与DDP化疗耐药有关。
OBJECTIVE： To determine the relation between the expression of ERCC1 and eisplatin resistance in non-small cell lung cancer （NSCLC）. METHODS： Use the strep tavidin-peroxidase complex technique to examine the expression of ERCC1 in 82 non-small cell lung cancer tissues and to study relationship between the expres- sion of ERCC1 and cisplatin in resistance in NSCLC. RESULTS： ERCC1 expression level did not show any association with patient age, sex, clinical stage and histology type（P〉0.05）. The response rate of cisplatin-based chemotherapy in negative group and over expression group of ERCC-1 were 53.5%（23/43）and 17.9%（7/39）; respectively, being a significant difference （X^2 =4.76, P=0.04）. The average survival. CONCLUSION： The expression of ERCC1 in NSCLC is re fated to cisplatin resistance, it shows predictive value to chemoresis tance in NSCLC.
出处
《中华肿瘤防治杂志》
CAS
2008年第19期1483-1485,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
云南省科技厅基金资助(07y10569)
关键词
癌
非小细胞肺
肺肿瘤/病理学
顺铂/药物疗法
carcinoma, non small cell lung
lung neoplasms/pathology
cisplatin/drug therapy
